Sex hormone related disorders, characterized by complex etiology and long-term health risks, pose a significant challenge to global health. Hormone-based therapies are often accompanied by adverse effects and fail to …
Endometriosis is a common, estrogen-driven chronic gynecologic disorder defined by the ectopic growth of endometrial-like tissue within the peritoneal cavity. Existing treatment options, primarily surgery and hormonal therapy, are limited …
Endometriosis is a prevalent condition characterized by persistent pelvic pain, which leads to distress and reduced quality of life. Currently, there is limited research examining the psychological factors associated with …
Endometriosis is a chronic inflammatory condition that causes significant physical and psychological distress. This study aimed to evaluate the therapeutic efficacy and safety of a combined oral contraceptive containing estetrol …
To evaluate the efficacy of oral gonadotropin-releasing hormone (GnRH) antagonists versus placebo for treatment of endometriosis-associated pain and to compare individual antagonists indirectly for dysmenorrhea and non-menstrual pelvic pain.
Background/Objective: This study evaluated the analgesic and anti-inflammatory effects of ambroxol in an experimental model of endometriosis. Methods: Ambroxol was administered at doses of 10, 50, and 100 mg/kg (Abx …
The purpose of this meta-analysis was to systematically assess the efficacy of ultrasound-guided therapy of ovarian endometriosis cyst (OEC). Several databases were searched to gather published studies on the efficacy …
BackgroundDespite many women learning about endometriosis on social media, posts about the condition often fail to reflect current evidence. With the content and credibility of online health messages being found …
Endometriosis is a chronic, estrogen-dependent inflammatory disease affecting about 10% of reproductive-age women. Chronic pelvic pain is its most disabling symptom, and available therapies often show limited long-term efficacy and …
Was the efficacy of linzagolix, observed at 6 months in women with endometriosis-associated pain, maintained when administered for an additional 6 months?